Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease

BACKGROUND: We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer’s disease (AD) in a proof-of-concept trial. METHODS: Twenty patients with AD [Mini Mental State Examination (MMSE) score 10–20 inclusive] with po...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Jeffrey L., Zhong, Kate, Kinney, Jefferson W., Heaney, Chelcie, Moll-Tudla, Joanne, Joshi, Abhinay, Pontecorvo, Michael, Devous, Michael, Tang, Anne, Bena, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731943/
https://www.ncbi.nlm.nih.gov/pubmed/26822146
http://dx.doi.org/10.1186/s13195-016-0173-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731943/
https://www.ncbi.nlm.nih.gov/pubmed/26822146
http://dx.doi.org/10.1186/s13195-016-0173-2

Ejemplares similares